Delivery Order 36F79718D0405-36C25924F0009
Award Date 10/5/23
Potential Completion Date 10/17/23
Potential Value $313K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Lawrenceville, Lawrence Township, NJ 08648, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Bristol-Myers Squibb Company was awarded a $310,935.67 delivery order for BREYANZI CAR T cell lymphoma therapy against the Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order was issued by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9, with work to be performed in Irving, Texas by April 1, 2024. Bristol-Myers Squibb will provide the chimeric antigen receptor (CAR) T cell immunotherapy BREYANZI under a firm fixed...
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Bristol-Myers Squibb Company under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The order is for the delivery of BREYANZI, a chimeric antigen receptor (CAR) T cell immunotherapy. The $310,935.67 firm-fixed price award has a period of performance through May 10, 2024, with all work to be performed in Lawrenceville, New Jersey. No set-aside designation was used...
- Bristol-Myers Squibb Company has been awarded a delivery order valued at $335,042.65 by Veterans Integrated Service Network 9 for the supply of BREYANZI CAR T therapy to support the transplant center operations. This firm fixed-price delivery order, awarded on October 27, 2025, with an ultimate completion date of February 6, 2026, will be performed in Lawrenceville, New Jersey. The award carries no set-aside designation, reflecting Bristol-Myers Squibb's status as a large biopharmaceutical...
- This is a federal contract award to Bristol-Myers Squibb Company, a global biopharmaceutical company, for its BREYANZI chimeric antigen receptor (CAR) T cell therapy. The $310,935.67 firm fixed price delivery order was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 9 and has an ultimate completion date of October 31, 2024. The award is not a set-aside contract. Bristol-Myers Squibb supplies the BREYANZI treatment, which is used to treat...
- <p>The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 (VA - VHA) awarded a $313,394.97 delivery order contract to Bristol-Myers Squibb Company Bristol Myers Squibb Division for the provision of BREYANZI. The prime contractor, Bristol-Myers Squibb Company, will perform under its Pharmaceuticals and Drugs Federal Supply Schedule contract. The firm fixed price order has a period of performance from January 30, 2023 through March 7, 2023.</p>
- <p>The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 (VA - VHA) awarded Bristol-Myers Squibb Company, doing business as Bristol-Myers Squibb, a $312,730.81 delivery order under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. Bristol-Myers Squibb will provide BREYANZI, an oncology treatment, to the VA from March 22, 2022 through April 19, 2022. The contract utilizes a firm fixed price payment structure.</p>
- The U.S. Department of Veterans Affairs (VA) awarded a firm-fixed-price delivery order contract to Bristol-Myers Squibb Company for the procurement of the cancer immunotherapy drug BREYANZI. The contract, valued at $335,042.65, has an ultimate completion date of May 14, 2025 and is placed under the company's existing Federal Supply Schedule contract (ID: 36F79724D0101) with the VA. This contract does not carry a set-aside designation, reflecting Bristol-Myers Squibb's status as a large...
- Bristol-Myers Squibb Company was awarded a $314,322.29 delivery order for emergency pharmaceutical ABECMA CAR T cell therapy under the Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order was issued by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 to provide the BCMA-directed CAR T immunotherapy to support TVHS programs. Work will be performed by Bristol-Myers Squibb in Lawrenceville, New Jersey through March...
- This is a delivery order contract awarded by the Department of Veterans Affairs Veterans Health Administration to Bristol-Myers Squibb Company, a global biopharmaceutical company. The contract is for the provision of ABECMA, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T immunotherapy. The delivery order has a ceiling value of $314,322.29 and is a firm fixed price contract with a period of performance from June 10, 2024 to July 9, 2024. The work will be performed...
- The Department of Veterans Affairs Veterans Health Administration awarded a delivery order contract to Bristol-Myers Squibb Company, doing business as Bristol-Myers Squibb, a global biopharmaceutical company. The $314,322.29 firm fixed price contract is for the provision of IDECABTAGENE VICLEUCEL, with a period of performance from March 20, 2024 to April 30, 2024. This delivery order is part of Bristol-Myers Squibb's broader Federal Supply Schedule contract with the Department of Veterans...